Machina Capital S.A.S. reduced its position in Kenvue Inc. (NYSE:KVUE – Free Report) by 77.7% in the 3rd quarter, Holdings Channel reports. The fund owned 56,142 shares of the company’s stock after selling 195,860 shares during the period. Machina Capital S.A.S.’s holdings in Kenvue were worth $991,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Johnson Financial Group Inc. acquired a new position in Kenvue in the 2nd quarter valued at $26,000. GK Wealth Management LLC acquired a new position in shares of Kenvue during the 3rd quarter valued at about $27,000. CoreCap Advisors LLC lifted its holdings in shares of Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 591 shares during the period. Bell Investment Advisors Inc purchased a new position in Kenvue during the second quarter worth approximately $35,000. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Kenvue in the 3rd quarter worth $36,000. 97.64% of the stock is owned by hedge funds and other institutional investors.
Kenvue Stock Performance
Kenvue stock opened at $19.31 on Friday. The firm’s 50-day moving average is $18.44 and its 200-day moving average is $18.27. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a 1 year low of $14.06 and a 1 year high of $20.13. The company has a market cap of $37.09 billion, a P/E ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48.
Kenvue (NYSE:KVUE – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $0.29 EPS for the quarter, meeting the consensus estimate of $0.29. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.86 billion. During the same period in the previous year, the business posted $0.28 EPS. The company’s quarterly revenue was up 3.2% on a year-over-year basis. On average, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were issued a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is currently 95.45%.
Wall Street Analyst Weigh In
KVUE has been the topic of several recent research reports. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. UBS Group raised their price objective on Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a research note on Monday, November 2nd. Barclays increased their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 21st. Weiss Ratings reiterated a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. Finally, HSBC dropped their price target on Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Ten analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $19.29.
Get Our Latest Analysis on KVUE
Kenvue Company Profile
Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.
Further Reading
- Five stocks we like better than Kenvue
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
